{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:29:01Z","timestamp":1794349741283,"version":"4.9.0"},"reference-count":158,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.neurot.2025.e00582","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T07:39:42Z","timestamp":1744270782000},"page":"e00582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Choosing initial MS therapy; personal, disease, and medication factors"],"prefix":"10.1016","volume":"22","author":[{"given":"Bruce A.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2025.e00582_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00582_bib2","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib3","doi-asserted-by":"crossref","first-page":"e787","DOI":"10.1212\/WNL.0000000000011242","article-title":"Effect of disease-modifying therapy on disability in multiple sclerosis over 15 years","volume":"96","author":"Kalincik","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00582_bib4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizuamb versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00582_bib5","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1474-4422(20)30342-2","article-title":"Long term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis:a post hoc analysis form the on-going open-label extension of the randomized, placebo- controlled, phase 3 trial","volume":"19","author":"Wolinski","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458516671204","article-title":"Shared decision-making in multiple sclerosis","volume":"23","author":"Colligan","year":"2017","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurot.2025.e00582_bib7","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00582_bib8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40271-023-00617-y","article-title":"Individual differences in the patient experience of relapsing multiple sclerosis (RMS): a multi-country qualitative exploration of drivers of treatment preferences among people living with rms","volume":"16","author":"Tatlock","year":"2023","journal-title":"The Patient-Patient-centered outcomes res"},{"key":"10.1016\/j.neurot.2025.e00582_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.msard.2019.07.005","article-title":"Patients' preferences and willingness to pay for disease modifying therapies","volume":"35","author":"Frost","year":"2019","journal-title":"Mult Scler Rel Disord"},{"key":"10.1016\/j.neurot.2025.e00582_bib10","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.msard.2018.11.016","article-title":"Understanding treatment decisions from the perspective of people with relapsing remitting multiple sclerosis: a critical interpretive synthesis","volume":"27","author":"Eskyte","year":"2019","journal-title":"Mult Scler Rel Disord"},{"key":"10.1016\/j.neurot.2025.e00582_bib11","article-title":"\u201cI'm walking into the unknown\u201d: qualitative insights into how the emotions and lived experience related to multiple sclerosis impact on decisions to pursue disease modifying treatment","volume":"58","author":"Carey","year":"2022","journal-title":"Mult Scler Rel Disord"},{"key":"10.1016\/j.neurot.2025.e00582_bib12","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1007\/s00213-018-5037-y","article-title":"Probability discounting of treatment decisions in multiple sclerosis: associations with disease knowledge, neuropsychiatric status and adherence","volume":"235","author":"Bruce","year":"2018","journal-title":"Psychpharmacol"},{"key":"10.1016\/j.neurot.2025.e00582_bib13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.7224\/1537-2073.2016-091","article-title":"Shared decision making and autonomy among US participants with multiple sclerosis in the NARCOMS registry","volume":"19","author":"Cofield","year":"2017","journal-title":"Int J MS care"},{"key":"10.1016\/j.neurot.2025.e00582_bib14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/hex.12599","article-title":"Comparison of preferences of healthcare professionals and MS patients for attributes of disease-modifying drugs: a best-worst scaling","volume":"21","author":"Kremer","year":"2018","journal-title":"Health Expect"},{"key":"10.1016\/j.neurot.2025.e00582_bib15","article-title":"Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS","volume":"50","author":"Sorensen","year":"2021","journal-title":"Mult Scler Rel Disord"},{"key":"10.1016\/j.neurot.2025.e00582_bib16","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/jamaneurol.2021.3416","article-title":"Health disparities, inequities, and social determinants of health in multiple sclerosis and related disorders in the US","volume":"78","author":"Amezcua","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40120-023-00573-7","article-title":"Insights for healthcare providers on shared decision-making in multiple sclerosis: a narrative review","volume":"13","author":"Stoll","year":"2024","journal-title":"Neurol Ther"},{"key":"10.1016\/j.neurot.2025.e00582_bib18","article-title":"Practical considerations for managing pregnancy in patients with multiple sclerosis","volume":"14","author":"Graham","year":"2024","journal-title":"Neurology: Clin Pract"},{"key":"10.1016\/j.neurot.2025.e00582_bib19","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/jnnp-2022-330533","article-title":"Postpartum relapse risk in multiple sclerosis: a systematic review and meta-analysis","volume":"94","author":"Schubert","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurot.2025.e00582_bib20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/13524585231197275","article-title":"The impact of medical insurance on health care access and quality for people with multiple sclerosis in the United States: a scoping review","volume":"30","author":"Moghavem","year":"2024","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurot.2025.e00582_bib21","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/WCO.0000000000000928","article-title":"Predicting disability worsening in relapsing and progressive multiple sclerosis","volume":"34","author":"Simmons","year":"2021","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib22","article-title":"Prognostic models for predicting clinical disease progression, worsening, and activity in people with multiple sclerosis","volume":"9","author":"Reeve","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurot.2025.e00582_bib23","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1093\/brain\/114.2.1045","article-title":"The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of ocutcome","volume":"114","author":"Weinshenker","year":"1991","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00582_bib24","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1191\/1352458503ms914oa","article-title":"Long-term follow up of patients with clinically isolated syndromes,relapsing-remitting and secondary progressive multiple sclerosis","volume":"9","author":"Eriksson","year":"2003","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2025.e00582_bib25","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/brain\/awq118","article-title":"The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability","volume":"133","author":"Scalfari","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00582_bib26","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1177\/1352458518790397","article-title":"Predicting the profile of increasing disability in multiple sclerosis","volume":"25","author":"Tomassini","year":"2019","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurot.2025.e00582_bib27","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/brain\/awg081","article-title":"Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process","volume":"126","author":"Confavreux","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00582_bib28","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/13524585231151951","article-title":"Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis","volume":"29","author":"Daruwalla","year":"2023","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurot.2025.e00582_bib29","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/brain\/awaa081","article-title":"Early clinical markers of aggressive multiple sclerosis","volume":"143","author":"Malpas","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00582_bib30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/brain\/116.1.117","article-title":"Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow up","volume":"116","author":"Runmarker","year":"1993","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00582_bib31","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1212\/WNL.0b013e31821e559d","article-title":"Demographic and clinical characteristics of malignant multiple sclerosis","volume":"76","author":"Gholipour","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00582_bib32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrneurol.2015.85","article-title":"Aggressive multiple sclerosis: proposed definition and treatment algorithm","volume":"11","author":"Rush","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib33","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1177\/1352458516665496","article-title":"Cognitive impairment predicts disability and cortical thinning in MS:an 8-year study","volume":"23","author":"Pitteri","year":"2017","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurot.2025.e00582_bib34","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ana.24938","article-title":"Prognostic indicators in pediatric clinically isolated syndrome","volume":"81","author":"Iaffaldano","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib35","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1191\/1352458503ms909oa","article-title":"Multiple sclerosis characteristics in African American patients in the New York state multiple sclerosis consortium","volume":"9","author":"Weinstock-Guttman","year":"2003","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2025.e00582_bib36","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1212\/01.WNL.0000145762.60562.5D","article-title":"Clinical characteristics of african americans vs caucasian americans with multiple sclerosis","volume":"63","author":"Cree","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00582_bib37","doi-asserted-by":"crossref","first-page":"e881","DOI":"10.1212\/WNL.0000000000012362","article-title":"Association of disease severity and socioeconomic status in black and white americans with multiple sclerosis","volume":"97","author":"Gray-Roncal","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00582_bib38","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1177\/1352458516679894","article-title":"Hispanic Americans and African Americans with multiple sclerosis have more severe disease course than Caucasian Americans","volume":"23","author":"Ventura","year":"2017","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurot.2025.e00582_bib39","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1177\/1352458511403025","article-title":"Multiple sclerosis in Hispanics:a study of clinical disease expression","volume":"17","author":"Amezcua","year":"2011","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurot.2025.e00582_bib40","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1212\/WNL.0000000000004025","article-title":"Racial disparities in neurologic health care access and utilization in the United States","volume":"88","author":"Saadi","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00582_bib41","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1212\/01.wnl.0000208505.81912.82","article-title":"Does multiple sclerosis-associated disability differ between races?","volume":"66","author":"Marrie","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00582_bib42","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/brain\/awv105","article-title":"Defining high, medium, and low impact prognostic factors for developing multiple sclerosis","volume":"138","author":"Tintore","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00582_bib43","article-title":"Current and future role of MRI in the diagnosis and prognosis of multiple sclerosis","volume":"44","author":"Rocca","year":"2024","journal-title":"Lancet Reg Health-Eur"},{"key":"10.1016\/j.neurot.2025.e00582_bib44","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaneurol.2019.3238","article-title":"Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis","volume":"77","author":"Bjornevik","year":"2020","journal-title":"JAMA Neuorl"},{"key":"10.1016\/j.neurot.2025.e00582_bib45","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jamaneurol.2023.3997","article-title":"Neurofilament light chain elevations and diablility progression in multiple sclerosis","volume":"80","author":"Abdelhak","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib46","doi-asserted-by":"crossref","first-page":"e2457","DOI":"10.1212\/WNL.0000000000009571","article-title":"Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis","volume":"94","author":"Manouchehrinia","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00582_bib47","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib48","doi-asserted-by":"crossref","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","article-title":"Blood neurofilament light chain as a biomarker of MS disease activity and treatment response","volume":"92","author":"Kuhle","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00582_bib49","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/jamaneurol.2023.0010","article-title":"Association of serum neurofilament light chain levels at disease onset with disability worsening in patients with a first demyelinating multiple sclerosis event not treated with high-efficacy drugs","volume":"80","author":"Monreal","year":"2023","journal-title":"JAMA Neurol"},{"issue":"suppl 1","key":"10.1016\/j.neurot.2025.e00582_bib50","first-page":"19","article-title":"Confounders affecting interpretation of neurofilament biomarkers in MS","author":"Khalil","year":"2021","journal-title":"Int J MS Care"},{"key":"10.1016\/j.neurot.2025.e00582_bib51","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/acn3.51704","article-title":"Associations of sNfl with clinico-radiological measures in a large MS population","volume":"10","author":"Sotirchos","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-33158-8","article-title":"Serum GFAP as a biomarker for disease severity in multiple sclerosis","volume":"8","author":"Abdelhak","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2025.e00582_bib53","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","article-title":"Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis","volume":"80","author":"Meier","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib54","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/acn3.51969","article-title":"Serum glial fibrillary acidic protein and disability in progressive multiple sclerosis","volume":"11","author":"Abdelhak","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib55","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200052","article-title":"Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis","volume":"10","author":"Barro","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurot.2025.e00582_bib56","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/jamaneurol.2024.0017","article-title":"Emerging cerebrospinal fluid biomarkers of disease activity and progression in multiple sclerosis","volume":"81","author":"Cross","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109688","article-title":"Clinical validation of a multi-protein, serum -based assay for disease activity assessments in multiple sclerosis","volume":"253","author":"Chitnis","year":"2023","journal-title":"Clin Immunol"},{"key":"10.1016\/j.neurot.2025.e00582_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756286419826547","article-title":"Evolution of clinical trials in multiple sclerosis","volume":"12","author":"Zhang","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurot.2025.e00582_bib59","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00582_bib60","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00582_bib61","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40263-022-00965-7","article-title":"High-efficacy therapies for treatment- na\u00efve individuals with relapsing multiple sclerosis","volume":"36","author":"Freeman","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neurot.2025.e00582_bib62","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2217\/nmt-2021-0058","article-title":"Updates and advances in multiple sclerosis therapeutics","volume":"13","author":"Amin","year":"2023","journal-title":"Neurodegener Dis Manag"},{"key":"10.1016\/j.neurot.2025.e00582_bib63","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1474-4422(11)70262-9","article-title":"Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomized trial","volume":"11","author":"Comi","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib64","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1212\/01.wnl.0000237641.33768.8d","article-title":"Treatment with interferon beta -1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes","volume":"67","author":"Kappos","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00582_bib65","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM200009283431301","article-title":"Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis","volume":"343","author":"Jacobs","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00582_bib66","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(07)61194-5","article-title":"Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study","volume":"370","author":"Kappos","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2025.e00582_bib67","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/jnnp-2016-314843","article-title":"Subcutaneous interferon \u03b2-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency -blind multicentre REFLEXION study","volume":"88","author":"Comi","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurot.2025.e00582_bib68","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1212\/WNL.53.8.1622","article-title":"Multiple sclerosis; side effects of interferon beta therapy and their management","volume":"53","author":"Walther","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00582_bib69","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1474-4422(08)70200-X","article-title":"Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the Rebif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomized, parallel, open-label trial","volume":"7","author":"Mikol","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib70","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1474-4422(09)70226-1","article-title":"250\u03bcg or 500\u03bcg interferon beta-1b versus 20mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomized, multicentre, study","volume":"8","author":"O'Connor","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib71","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(09)61259-9","article-title":"Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomized, double-blind, placebo-controlled trial","volume":"374","author":"Comi","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2025.e00582_bib72","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.23938","article-title":"Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis","volume":"73","author":"Khan","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib73","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1017\/S0317167100002845","article-title":"Lipoatrophy in patients with multiple sclerosis on glatiramer acetate","volume":"31","author":"Edgar","year":"2004","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.neurot.2025.e00582_bib74","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1474-4422(14)70191-7","article-title":"Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Miller","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib75","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2023.2815","article-title":"Teriflunomide and time to clinical multiple sclerosis in patients with radiologically isolated syndrome","volume":"80","author":"Leburn-Frenay","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib76","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2217\/nmt-2021-0014","article-title":"An updated review of teriflunomide's use in multiple sclerosis","volume":"11","author":"Miller","year":"2021","journal-title":"Neurodegener Dis Manag"},{"key":"10.1016\/j.neurot.2025.e00582_bib77","article-title":"Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: results from the TOWER extension study","volume":"46","author":"Miller","year":"2020","journal-title":"Mult Scler Rel Disord"},{"key":"10.1016\/j.neurot.2025.e00582_bib78","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00582_bib79","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or Glatiraamer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00582_bib80","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/1352458514537013","article-title":"Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS)","volume":"21","author":"Gold","year":"2015","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurot.2025.e00582_bib81","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ana.26555","article-title":"Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome","volume":"93","author":"Okuda","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib82","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.30439","article-title":"Effect of dimethyl fumarate vs interferon \u03b2=1a n patients with pediatric-onset multiple sclerosis","volume":"5","author":"Vermersch","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.neurot.2025.e00582_bib83","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1177\/13524585211037909","article-title":"Long -term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: final ENDORSE study results","volume":"28","author":"Gold","year":"2022","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurot.2025.e00582_bib84","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/1352458520949158","article-title":"Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients","volume":"28","author":"Jordan","year":"2022","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurot.2025.e00582_bib85","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00582_bib86","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00582_bib87","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jamaneurol.2020.2950","article-title":"Efficacy and safety of 2 fingolimod doses vs glatiramer acetate for the treatment of patients with relapsing-remitting multiple sclerosis: a randomized clinical trial","volume":"78","author":"Cree","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib88","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(21)00244-0","article-title":"Sphingosine-1-phosphate receptor modulators in multiple sclerosis and other conditions","volume":"398","author":"McGinley","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2025.e00582_bib89","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40263-021-00798-w","article-title":"Sphingosine 1-phosphate receptor modulators for multiple sclerosis","volume":"35","author":"Roy","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neurot.2025.e00582_bib90","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jns.2013.02.011","article-title":"Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy","volume":"328","author":"Groves","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurot.2025.e00582_bib91","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","article-title":"Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomized, double-blind, placebo-controlled trial","volume":"387","author":"Lublin","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2025.e00582_bib92","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","article-title":"Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment","volume":"73","author":"Hatcher","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib93","article-title":"Frequency and risk factors of rebound after fingolimod discontinuation-a retrospective study","volume":"81","author":"Maunula","year":"2024","journal-title":"Mult Scler Rel Disord"},{"key":"10.1016\/j.neurot.2025.e00582_bib94","article-title":"Incidence and risk of infection associated with fingolimod in patients with multiple sclerosis: a systematic review and meta-analysis of 8448 patients from 12 randomized controlled trials","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurot.2025.e00582_bib95","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib96","doi-asserted-by":"crossref","first-page":"e1815","DOI":"10.1212\/WNL.0000000000005529","article-title":"Progressive multifocal leukoencephalopathy after fingolimod treatment","volume":"90","author":"Berger","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00582_bib97","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001156","article-title":"Cryptococcal meningitis reported with fingolimod treatment","volume":"9","author":"Del Poeta","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurot.2025.e00582_bib98","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.0000000000001302","article-title":"Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis","volume":"84","author":"Kappos","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00582_bib99","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1212\/WNL.0b013e318248deea","article-title":"Fingolimod-associated macular edema. Incidence, detection and management","volume":"78","author":"Jain","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00582_bib100","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/acn3.52017","article-title":"Sphingosine 1-phosphate modulators in multiple sclerosis treatment: a practical review","volume":"11","author":"Coyle","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib101","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2025.e00582_bib102","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1177\/13524585221083194","article-title":"Long-term efficacy and safety of Siponimod in patients with secondary progressive multiple sclerosis: analysis of EXPAND core and extension data up to >5years","volume":"28","author":"Cree","year":"2022","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurot.2025.e00582_bib103","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis(RADIANCE):a multicentre, randomized, 24 month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib104","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomized, 12- month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib105","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1177\/13524585221102584","article-title":"Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: up to 5 years of follow-up in the DAYBREAK open -label extension trial","volume":"28","author":"Cree","year":"2022","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurot.2025.e00582_bib106","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","article-title":"Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study","volume":"78","author":"Kappos","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib107","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","article-title":"Cladribine: mode of action and implications for treatment of multiple sclerosis","volume":"34","author":"Leist","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.neurot.2025.e00582_bib108","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00582_bib109","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results form the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannonni","year":"2018","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurot.2025.e00582_bib110","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","article-title":"Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomized trial","volume":"13","author":"Leist","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib111","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1177\/13524585241267211","article-title":"Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab, and alemtuzumab in relapsing-remitting multiple sclerosis","volume":"30","author":"Roos","year":"2024","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurot.2025.e00582_bib112","unstructured":"Mavenclad prescribing information 5\/2024. www.emdserono.com\/us-en\/pi\/mavenclad-pi.pdf."},{"key":"10.1016\/j.neurot.2025.e00582_bib113","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00582_bib114","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","article-title":"Comparison of switching to 6-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomized, controlled, open-label, pivotal 3b trial","volume":"31","author":"Foley","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.549842","article-title":"Natalizumab in multiple sclerosis treatment: from biological effects to immune monitoring","volume":"11","author":"Khoy","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurot.2025.e00582_bib116","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00582_bib117","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib118","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib119","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1177\/1352458519854162","article-title":"Should frequent MRI monitoring be performed in natalizumab-treated MS patients. A contribution to a recent debate","volume":"26","author":"Scarpazza","year":"2020","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurot.2025.e00582_bib120","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1212\/WNL.0000000000004485","article-title":"Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients","volume":"89","author":"Plavina","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00582_bib121","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1352458516641775","article-title":"Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawl","volume":"23","author":"Larochelle","year":"2017","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurot.2025.e00582_bib122","unstructured":"Natalizumab, NIH lactation database. October 15,2024. ncbi.nlm.nih.gov\/books\/NBK501613\/."},{"key":"10.1016\/j.neurot.2025.e00582_bib123","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta-1a as first-line therapy for patients with relapsing-remitting multiple sclerosis: a randomized controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2025.e00582_bib124","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.0000000000004313","article-title":"Alemtuzumab CARE-MS I 5-year follow up","volume":"89","author":"Havrdova","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00582_bib125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17562864231194823","article-title":"Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label Topaz study","volume":"16","author":"Coles","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurot.2025.e00582_bib126","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1756285614563522","article-title":"Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use","volume":"8","author":"Havrdova","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurot.2025.e00582_bib127","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.msard.2018.05.014","article-title":"Mortality from listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing- remitting multiple sclerosis","volume":"24","author":"Canham","year":"2018","journal-title":"Mult Scler Rel Disord"},{"key":"10.1016\/j.neurot.2025.e00582_bib128","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/WCO.0000000000000700","article-title":"Current therapeutic landscape in multiple sclerosis: evolving treatment paradigm","volume":"32","author":"Cree","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib129","unstructured":"Lemtrada prescribing information, 5\/2024. https:\/\/products.sanofi.us\/lemtrada\/lemtrada.pdf."},{"key":"10.1016\/j.neurot.2025.e00582_bib130","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/ana.25119","article-title":"B-cell therapy for multiple sclerosis: entering an era","volume":"83","author":"Greenfield","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib131","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awm038","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00582_bib132","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00582_bib133","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00582_bib134","doi-asserted-by":"crossref","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","article-title":"Five years of ocrelizumab in relapsing multiple sclerosis","volume":"95","author":"Hauser","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00582_bib135","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1474-4422(20)30342-2","article-title":"Long-term follow -up from the ORATORIO trial of \u200b ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomized, placebo, -controlled, phase 3 trial","volume":"19","author":"Wolinsky","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib136","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210142","article-title":"Long-term treatment with ocrelizumab in patients with early-stage relapsing MS; 9-year data from the OPERA studies open-label extension","volume":"104","author":"Cerqueira","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00582_bib137","unstructured":"Zunovo prescribing information. 9\/2024. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761371s000lbl."},{"issue":"17 supplement 1","key":"10.1016\/j.neurot.2025.e00582_bib138","article-title":"OCARINA II, phase III study results of subcutaneous ocrelizumab administration in patients with multiple sclerosis (S31.006)","volume":"102","author":"Newsome","year":"2024","journal-title":"Neuology"},{"key":"10.1016\/j.neurot.2025.e00582_bib139","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"issue":"17_supplement_1","key":"10.1016\/j.neurot.2025.e00582_bib140","article-title":"Longer -term(up to 6 years) efficacy of ofatumumab in people with recently diagnosed and treatment-na\u00efve relapsing multiple sclerosis (S31.003)","volume":"102","author":"Pardo","year":"2024","journal-title":"Neurology"},{"issue":"17_supplement_1","key":"10.1016\/j.neurot.2025.e00582_bib141","article-title":"Earlier initiation of ublituximab treatment is associated with improved disability among treatment-na\u00efve participants in Ultimate I and II. (P9-6.001)","volume":"102","author":"Robertson","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00582_bib142","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/ana.27012","article-title":"COMBAT-MS: a population-based observational cohort study addressing the benefit-risk balance of multiple sclerosis therapies compared with rituximab","volume":"96","author":"Piehl","year":"2024","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib143","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib144","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamaneurol.2023.1625","article-title":"Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis","volume":"80","author":"Roos","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib145","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40265-024-02011-w","article-title":"Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety and tolerability","volume":"84","author":"Carlson","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.neurot.2025.e00582_bib146","article-title":"Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management","volume":"79","author":"Alvarez","year":"2023","journal-title":"Mult Scler Rel Disord"},{"key":"10.1016\/j.neurot.2025.e00582_bib147","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1177\/13524585231195854","article-title":"Immune-mediated colitis associated with ocrelizumab: a new safety risk","volume":"29","author":"Kim","year":"2023","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurot.2025.e00582_bib148","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","article-title":"Effect of ocrelizumab on vaccine responsesin patients with multiple sclerosis","volume":"95","author":"Bar-Or","year":"2020","journal-title":"Neurology"},{"issue":"17_supplement_1","key":"10.1016\/j.neurot.2025.e00582_bib149","article-title":"10 years of ocrelizumab treatment in multiple sclerosis: long-term efficacy and safety clinical trial data (S31.005)","volume":"102","author":"Hauser","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00582_bib150","unstructured":"Drugs and Lactation Database. Ocrelizumab July 15, 2024. Ncbi.nlm.nih.gov\/books\/NBK500903."},{"key":"10.1016\/j.neurot.2025.e00582_bib151","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ncl.2023.06.004","article-title":"Highly effective therapy versus escalation approaches in early multiple sclerosis","volume":"42","author":"Rjeily","year":"2024","journal-title":"Neurol Clin"},{"key":"10.1016\/j.neurot.2025.e00582_bib152","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00415-023-11969-8","article-title":"Multiple sclerosis: time for early treatment with high efficacy drugs","volume":"271","author":"Selmaj","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib153","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00582_bib154","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib155","doi-asserted-by":"crossref","first-page":"e1041","DOI":"10.1212\/WNL.0000000000010135","article-title":"Initial high-efficacy disease-modifying therapy in multiple sclerosis","volume":"95","author":"Buron","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00582_bib156","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00415-021-10673-9","article-title":"Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity matched study","volume":"269","author":"Hanninen","year":"2022","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib157","first-page":"175","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00582_bib158","unstructured":"FDA drug safety communication. 1\/22\/2025. fda.gov\/safety\/medical-product-safety-information\/Copaxone-glatopa-glatiramer-acetate-drug-safety-communication-fda-adds-boxed-warning-about-rare-but-serious-allergic-reaction-called-anaphylaxis.."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T13:00:56Z","timestamp":1755090056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925000601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":158,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1878747925000601"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00582","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Choosing initial MS therapy; personal, disease, and medication factors","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00582","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00582"}}